INOVIQ

Investor Presentation

Bell Potter Healthcare Conference 2023

Disclaimer

This presentation has been prepared by INOVIQ Limited ("INOVIQ" or the "Company") based on information available to it as at the date of this presentation. This presentation contains general and background information about the Company's activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the information that an investor should consider when making an investment decision and does not contain all information about the Company's assets and liabilities, financial position and performance, profits and losses, prospects, and the rights and liabilities attaching to the Company's securities necessary to make an investment decision. The information in this presentation should be read in conjunction with the Company's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange (ASX), available at www.asx.com.au. The information in this presentation is based on the Company's own information and estimates and has not been independently verified. The Company is not responsible for providing updated information and assumes no responsibility to do so. Any investment in the Company should be considered speculative and there is no guarantee that they will make a return on capital invested, that dividends would be paid, or that there will be an increase in the value of the investment in the future.

This Presentation may contain certain "forward-looking statements" that are based on management's beliefs, assumptions and expectations and on information currently available to management. The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Any indications of, and guidance on, future operating performance, earnings, financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions.

Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including INOVIQ or any of its advisers). In particular, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward-looking statements in this Presentation will actually occur. Actual operations, results, performance, targets or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based.

Nothing contained in this Presentation constitutes investment, legal, tax or other advice. This Presentation does not purport to be all inclusive or to contain all information which its recipients may require in order to make an informed assessment of the Company's prospects.

You should note that any past performance is given for illustrative purposes only and should not be relied on as (and is not) an indication of the Company's views on its future financial performance or condition. Past performance, including past share price performance, of INOVIQ cannot be relied on as an indicator of (and provides no guidance as to) future performance including future share price performance.

Company snapshot

Precision focus
Precision diagnostic and exosome solutions to improve patient outcomes

Disruptive technology
Proprietary technology platforms driving future products for cancer and other diseases

Deep pipeline
Multi-stage pipeline including SubB2M diagnostics, exosome research tools and exosome diagnostics

Compelling data
High accuracy exosome isolation tools and diagnostics for breast and ovarian cancers

Commercial products
Commercial exosome isolation tools and bladder cancer detection test

Partnering for growth
Partnering with KOLs and Industry to deliver clinical and commercial outcomes

Financial information (ASX:IIQ)	
Ordinary shares[2]	92,018,702
Listed options[2]	2,611,349
52-week H/L[2]	A$0.990-0.460
Share price[2]	A$0.60
Market capitalisation[2]	A$55.2m
Cash at bank[1]	A$6.3m
Major shareholders (as at 10 November 2023)	
Merchant Funds Mgt Pty Ltd	14.2%
Moggs Creek/Lawn Views Pty Ltd	5.3%

Share price performance

INOVIQ

DR GEOFF CUMMING
Non-Executive Chairman

Healthcare and biotechnology director with extensive diagnostics industry experience.

Previously Managing Director Roche Diagnostic Systems (Oceania), MD/CEO Biosceptre International Ltd and MD/CEO of Anteo Diagnostics Ltd.

Currently NED AnteoTech Ltd.

MAX JOHNSTON
Non-Executive Director

Healthcare industry director and international business leader with extensive experience across medtech, pharmaceuticals, consumer healthcare and consumer goods.

Previously President and CEO of Johnson & Johnson Pacific, Chairman of AusCann Ltd, NED of PolyNovo Ltd, Medical Developments International Ltd, Tissue Repair Ltd and CannPal Animal Therapeutics Ltd.

PHILIP POWELL
Non-Executive Director

Healthcare industry director and chartered accountant with extensive investment banking experience specialising in capital raisings, IPOs, mergers and acquisitions and other transactions across pharma, food and agriculture.

Previously at OAMPS Ltd and Arthur Andersen, and NED at Polynovo Ltd and Medical Developments International Ltd.

Currently NED RMA Global Ltd.

DR LEEARNE HINCH
Chief Executive Officer

Biotechnology CEO with a successful track record in corporate development, capital raising, product development, commercialisation and licensing.

Past leadership and consulting roles in ASX-listed biotechnology, multinational and private companies across diagnostics, devices, therapeutics and animal health including Eustralis Pharmaceuticals, HealthLinx, OBJ, Holista Colltech, Virbac and Mars.

DR GREG RICE
Chief Scientific Officer

Internationally recognized, award winning scientist with over 35 years' experience and a successful track record in oncology research, exosome science, biomarker discovery, and diagnostics development.

Previous leadership roles in academia and industry including at Uni Queensland Centre for Clinical Research, Baker Heart Institute, University of Melbourne, Monash University and HealthLinx.

MARK EDWARDS
CFO & Company Secretary

Highly experienced finance executive with expertise in financial leadership and management, corporate governance, investor relations and corporate transactions.

Previous senior roles in ASX listed pharmaceutical, medical device and healthcare companies, including Medical Developments International and Cogstate.

INOVIQ

Focused on advancing the development and commercialisation of our SubB2M and EXO-NET platforms

✓ Clinically validated **SubB2M technology** and commenced BC monitoring study to enable partnering for LDT commercialisation

✓ Developed, validated and commissioned **high-throughput EXO-NET** exosome isolation system to enable a complete exosome concept-to-clinic diagnostics solution

✓ Secured **commercial partners** for EXO-NET with Promega and ResearchDx to drive future revenues

✓ Progressed **pipeline** of EXO-NET research tools, SubB2M tests and exosome diagnostics

✓ Initiated discussions for potential **co-development** of exosome diagnostics (using EXO-NET)

✓ Expanded Board with the appointment of experienced director, **David Williams**, as Chairman elect[1]

Excellent clinical data for SubB2M/CA15-3 breast cancer test announced

INOVIQ

INOVIQ announces global joint marketing agreement with Promega

Promega   INOVIQ

INOVIQ & ResearchDX

EXO-NET

Sign a license and supply agreement for the provision of EXO-NET enabled diagnostic services in the USA

1. Subject to shareholder approval at upcoming INOVIQ AGM on 29 Nov 23

INOVIQ

STRATEGIC FOCUS

Leading exosome solutions and precision diagnostics company focused on improving patient outcomes for cancer

DISRUPTIVE TECHNOLOGY

EXO-NET immunoaffinity magnetic bead–based exosome isolation

SubB2M technology for enhanced cancer detection

EXO-ACE ion exchange chromatography for therapeutic exosome production

RESEARCH TOOLS & SERVICES

EXO-NET products
EXO-NET services

DIAGNOSTICS

SubB2M diagnostics
Exosome diagnostics
hTERT test

THERAPEUTICS

Exosome therapeutics

INOVIQ

Products and pipeline | multi-stage research tools and cancer diagnostics

- Exosome research tools for **exosome isolation**, biomarker discovery and diagnostics development
- Blood tests for **earlier and more accurate detection** of breast, ovarian and other cancers

PRODUCT	INDICATION	USE	RESEARCH	ASSAY DEVELOPMENT	CLINICAL DEVELOPMENT	MARKET
hTERT[1]	Bladder Cancer	Adjunct to cytology			IVD-Class 1 USA	
SubB2M-BC	Breast Cancer	Monitoring		LDT		
SubB2M-OC	Ovarian Cancer	Monitoring		LDT		
SubB2M-SPR	Multi-cancer	Pre-screening	LDT			
EXO-OC[2]	Ovarian Cancer	Screening		LDT		
EXO-NET RUO	pan-EV capture	Research tool				RUO
TEXO-NET RUO	tumour derived-EV capture	Research tool	RUO			
NEURO-NET RUO	brain derived-EV capture	Research tool	RUO			

SubB2M Dx / *EXO tools/Dx*

NOTE: Development pipeline is indicative only, subject to review.

*EV = Extracellular Vesicles ; ICC = Immunocytochemistry; IVD = In Vitro Diagnostic; LDT = Laboratory-Developed Test; RUO = Research Use Only
1. Adjunct to urine cytology to assist the detection of bladder cancer; 2 Umbrella Research & Option Agreement with the University of Queensland

INOVIQ

Scientific rationale

- Cancer cells have a distinct feature of adding different sugar molecules to the proteins they produce, which sets them apart from normal cells

- **Neu5Gc** is a sugar molecule commonly found in cancer cells

- **SubB2M** is an engineered protein that preferentially binds to Neu5Gc

- SubB2M is a promising **multicancer probe**

- Incorporating SubB2M into existing cancer biomarker tests, may **improve sensitivity and specificity** for detecting various types of cancer

Changes in protein glycosylation

Cellular transformation and progression

neu5Gc
neu5Ac

Normal cells
Expressing **Neu5Ac** glycoproteins

Malignant cells
Expressing **Neu5Gc** glycoproteins

Neu5Gc = the sialic acid, N-glycolylneuraminic acid

INOVIQ

SubB2M/CA15-3 test | Breast Cancer monitoring

Clinical-stage and progressing towards partner-ready by Dec 2023 to enable LDT commercialisation

Breast cancer
- **#1 cancer in women**
- 2.3m new cases of breast cancer worldwide pa[1]
- 7.8m survivors (5-year)[1]

Unmet medical need
- **Earlier and more accurate detection** and monitoring tests required for breast cancer
- **US$4.2b** global diagnostics market[2]

Disruptive technology
- **SubB2M** is an engineered protein that specifically binds the pan-cancer biomarker Neu5Gc[3]
- Improved immunoassay for detection of Neu5Gc decorated **CA15-3**
- Increased sensitivity and specificity to detect cancer over existing assays

Intended use
- Aid in **monitoring** breast cancer treatment response and disease recurrence in women previously diagnosed with disease

Go-to-market strategy
- **LDT** then IVD (510k/PMA process)
- Partner with a CLIA-accredited laboratory

Development stage

Stage	Status
Feasibility	Completed
Assay development	Completed
Analytical validation (n=94)	Completed
Clinical validation (n=483)	Completed
Monitoring study	H2 CY23
LDT partner ready	Dec 2023

510k = FDA clearance for Class II device; CLIA = Clinical Laboratory Improvement Amendments (high-complexity tests) ; IVD = In Vitro Diagnostic; LDT = Laboratory Developed Test;
1. https://gco.iarc.fr/today/home; 2. https://www.grandviewresearch.com/industry-analysis/breast-cancer-diagnostics-market; 3 Neu5Gv = the sialic acid, N-glycolylneuraminic acid

INOVIQ

Clinical validation study | completed

- Retrospective, case-control, **clinical validation study** in 483-samples demonstrated **SubB2M/CA15-3 test detected breast cancer across all stages with high accuracy** (AUC 0.93, 81% sensitivity and 93% specificity) and **outperformed a leading approved CA15-3 test**[1]

## Breast Cancer monitoring study | commenced

- 2-phase **monitoring study** in over 200-samples to evaluate performance of SubB2M/CA15-3 test as an aid for monitoring treatment response and/or disease recurrence compared to approved CA15-3 test
- Data expected Dec-23

SubB2M/CA15-3 and compar**ator** CA15-3 test performance summary		
Breast Cancer All Stages	**SubB2M**	**Comparator**
AUC	0.93	0.70
sensitivity	81%	37%
specificity	93%	88%
false negative rate	19%	63%
false positive rate	7%	12%
positive predictive value	92%	75%
negative predictive value	83%	58%
overall accuracy	87%	63%

**Test Sensitivity by stage @95% Specificity**

Breast cancer (n=241: I=75, II=72, 3=72, III=72, IV = 22) and healthy controls (n=242)

1. SubB2M/CA15-3 clinical validation results (ASX: 27/6/23)

INOVIQ

Study 1: To determine whether SubB2M/CA15-3 is equally expressing in women with different subtypes of breast cancer

Pre-treatment serum
- Hormone receptor breast cancer (n=50)
- Her2 positive breast cancer (n=50)
- Triple Negative breast cancer (n=50)
- Age matched controls (n=65)

SubB2M/CA15-3 test

IVD CA15-3 test

comparison between types of BC

comparison between test

INOVIQ

Study 2: To determine the accuracy of SubB2M/CA15-3 to identify breast cancer recurrence

Progressing towards clinical validation

| Ovarian cancer	• #8 cancer in women & **deadliest gynaecological cancer** • 314k new cases of ovarian cancer worldwide pa[1] • 823k survivors (5-year)[1]
Unmet medical need	• **Earlier and more accurate detection** and monitoring tests required for ovarian cancer • **US$1.8b** global diagnostics market[2]
Disruptive technology	• **SubB2M** is an engineered protein that specifically binds the pan-cancer biomarker Neu5Gc • Improved immunoassay for detection of Neu5Gc decorated **CA125** • Increased sensitivity and specificity to detect cancer over existing assays
Intended use	• Aid in **monitoring** ovarian cancer treatment response and disease recurrence in women previously diagnosed with disease
Go-to-market strategy	• **LDT** then IVD (510k/PMA process) • Partner with a CLIA-accredited laboratory

Development stage

Feasibility	Completed
Assay development	H2 CY23
Analytical validation	H2 CY23
Clinical validation	H2 CY23
Monitoring study	H1 CY24
LDT partner ready	Jun 2024

INOVIQ

SubB2M/CA15-3 test is expected to be partner-ready in December 2023 for commercialisation as a Laboratory Developed Test

**Build analytical and clinical validation data package**

Commercialise first as an LDT in the USA with a lab partner to generate early revenue

Complete IVD medical device development and regulatory approval via 510k / PMA pathway

Secure IVD partners and approvals in major markets to expand geographic reach and grow revenue

510k = FDA clearance for Class II device; CLIA = Clinical Laboratory Improvement Amendments (high-complexity tests) ; CMS = Centers for Medicare and Medicaid Services; IVD = In Vitro Diagnostic; FDA = US Food & Drug Administration; LDT = Laboratory Developed Test; MDR = Medical Device Regulations; OC = Ovarian Cancer; PMA = FDA premarket approval for Class III device; KOL = Key Opinion Leader

INOVIQ

Market potential | Screening and monitoring tests

	Statistics[1]	Eligible screening population[2]	Eligible monitoring population[3]	Global Market size[4,5]
Ovarian cancer ■ EU5 ■ US ■ AU	**Ovarian cancer incidence** 52,638 / **Ovarian cancer prevalence** 154,831	4.0 / 60.4 / 54.7 **119m** (Millions of people)	11.5 / 188.3 / 167.3 **367k** (Thousands of people)	**$1.9b** GLOBAL Dx MARKET (US$ billions)
Breast cancer ■ EU5 ■ US ■ AU	**Breast cancer incidence** 543,972 / **Breast cancer prevalence** 2,279,467	4.0 / 60.4 / 54.7 **119m** (Millions of people)	0.2 / 2.2 / 2.1 **4.46m** (Millions of people)	**$4.2b** GLOBAL Dx MARKET (US$ billions)

INOVIQ

# Exosomes | Diagnostic and therapeutic potential

- Exosomes are released by cells and perform key roles in **intercellular communication, immune regulation and pathogenesis**

- Diseases elicit changes in the release of exosomes and their **molecular cargo** (DNA, RNA and proteins)

- Exosomes can be isolated from biofluids (including blood, urine and saliva) and their messages "read" to diagnose the **health** or **disease status** of the parent cell

- Exosome **diagnostics and therapeutics** are being developed for oncology, neurology, cardiology, immunology, inflammatory and other diseases

- Commercial potential limited by **time-consuming and inefficient exosome isolation** methods that are not suitable for commercial applications

- INOVIQ has developed **fast, efficient and scalable** exosome isolation technology

| **US$661m** Exosome research market[1] | **US$8.7b** Exosome diagnostic & therapeutic market[2] |

INOVIQ

Immunoaffinity magnetic bead-based capture system for isolation and analysis of exosomes

Rapid, Simple, Cost-effective

Compatible downstream analysis
Enriches relevant EVs
Reproducible

Scalable
Full automation

Compatible with path lab workflow and platforms

cGMP

EXO-NET research tools and services | commercially available

EXO-NET PAN-EXOSOME CAPTURE

EXO-NET is a research tool for fast, efficient & scalable exosome isolation from plasma, serum, urine, saliva and cell-conditioned media[1,2,3]

CUSTOMISED EXO-NET TOOLS

Design custom EXO-NET tools using ligands for specific EV populations

EXOSOME ISOLATION

EV isolation using EXO-NET powered, fully-automated, high-throughput platform[1]

BIOMARKER DISCOVERY

Biomarker discovery to identify, evaluate and validate EV-based RNA and Protein biomarkers

DIAGNOSTICS DEVELOPMENT

EV-based clinical diagnostics, clinical trial assays and companion diagnostics

1. EXO-NET data at ISEV (ASX: 19/5/23); 2. Promega EXO-NET Co-marketing Agreement (ASX: 6/7/23); 3. ResearchDx EXO-NET Services Licence (ASX 5/9/23)

SubB2M and EXO-NET programs moving towards key inflection points

H2 CY 2023	H1 CY 2024
✅ EXO-NET co-marketing agreement with Promega	● Commercial progress SubB2M/CA15-3 LDT
✅ Results of EXO-OC equivalence study in plasma and serum (n=250)	● Results SubB2M/CA125 OC clinical validation studies
● Results SubB2M SPR feasibility study	● NEURO-NET data
● Results SubB2M/CA125 OC analytical validation study	● New EXO-NET collaborations / partnering
● Results of SubB2M/CA15-3 BC monitoring study	● Progress EXO-OC test collaboration and clinical data
● Progress SubB2M partnering	
✅ TEXO-NET data @ ANZSEV23 meeting	

INOVIQ

1 **Innovative Company**

Focused on next-gen diagnostic and exosome solutions to improve health outcomes in cancer and other diseases

2 **Patented Technology**

Proprietary SubB2M & NETs technologies with multiple diagnostic and therapeutic applications

3 **Strong Pipeline**

Deep pipeline for detection of common and/or deadly cancers

4 **Compelling Results**

Data for SubB2M and exosome-based tests demonstrating earlier and more accurate detection for breast & ovarian cancers

5 **Commercialized Products**

Products in-market for exosome isolation and bladder cancer detection

6 **Partnering for Growth**

Commercialisation through partnering to deliver solutions to global markets

7 **Experienced Leadership**

Track record in healthcare leadership, exosome science, diagnostic development and commercialisation

8 **Funding our Future**

Cash of $6.3m as at 30 Sep 23 to fund operations and pipeline development

20

INOVIQ

Contacts

INOVIQ Ltd
23 Normanby Road
Notting Hill VIC 3168
Australia

P +61 3 9548 7586
E info@inoviq.com
W www.inoviq.com

Dr Leearne Hinch | CEO
E lhinch@inoviq.com
M +61 400414416

INOVIQ